An interventional study of Left bundle branch pacing lead and Right ventricular active fixation lead in Pacemaker DDD and Heart Block, sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-11.
Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
High burden right ventricular (RV) pacing has been shown to increase cardiovascular mortality, incidence of heart failure (HF), worsen left ventricular (LV) function and accelerate the development of atrial fibrillation (AF). High percentage ventricular pacing and wider paced QRS in the setting of normal baseline LV ejection fractions have consistently been shown to be independent risk factors for pacing-induced cardiomyopathy. Left bundle branch pacing (LBBP) has emerged as a potential alternative pacing mechanism that may avoid LV dyssynchrony and pacing-induced LV dysfunction by mimicking native electrical conduction.
We hypothesize that in patients with high degree AV block with anticipated ventricular pacing >90%, and an EF >35% patients undergoing LBBP will demonstrate a significantly lower number of the primary composite endpoint of cardiovascular death, heart failure events, and change in LVESVi as compared to standard RV pacing. Echos will be performed at baseline, 12, 24, and 36 months. NTproBNPs are performed at baseline and follow-up. There will be a core echo lab, and blinded adjudication of ECGs and events.
39 studies on the registry are indexed under Heart Block; 12 are open to participants now.
This study's planned enrollment of 1,300 is above the median of 104 across 24 interventional studies indexed under Heart Block.
Browse Heart Block studies →McGill University Health Centre/Research Institute of the McGill University Health Centre is the lead sponsor of 422 studies on the registry; 106 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with an indication for ventricular pacing and high-degree atrioventricular block where the degree of anticipated RV pacing is >90% including:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Left bundle branch pacing lead
Device: Right ventricular active fixation lead
Implantation of a left bundle branch pacing lead via sheath, to perform selective or non-selective pacing
Active fixation lead (standard)
Time to cardiovascular death
Clinical
Time frame: 36 months
Time to first heart failure event
Defined as: (i) Emergency department (ED) visits or hospitalization for HF (requiring signs and symptoms consistent with congestive heart failure (CHF) that is responsive to oral or parenteral medications); (ii) intensification of therapy (intravenous diuretic therapy on an outpatient basis); or (iii) indication for device upgrade to CRT due to deteriorating LV function defined as an absolute decline in LVEF ≥ 10% from baseline and an LVEF ≤ 40%
Time frame: 36 months
Worsening LV end systolic volume index by 2 years
Defined as a 15% increase from baseline each year up to the two-year echo
Time frame: 24 months
Cardiovascular mortality
CV-related
Time frame: 24 months
New visit for Heart Failure
Heart failure visit is defined as: i) Emergency department visit or hospitalization for signs and symptoms of HF that is responsive to oral or intravenous diuretics ii) intensification of therapy defined as outpatient intravenous diuretic therapy, and iii) device upgrade to cardiac resynchronization therapy.
Time frame: 24 months
Total mortality
Total mortality
Time frame: 24 months
Change in left ventricular ejection fraction
Echo parameter, change from baseline to 24 months
Time frame: 24 months
Change in NTproBNP level
From baseline to 24 months
Time frame: 24 months
Atrial fibrillation progression
Atrial fibrillation burden as noted on pacemaker
Time frame: 24 months
Development of new tricuspid regurgitation
More than mild TR from baseline
Time frame: 24 months
Presence of Mitral regurgitation
Progression/Development from baseline
Time frame: 24 months
Change in Lead parameter
stability of impedance, sensing, thresholds
Time frame: 24 months
Quality of Life Improvement
Health related quality of life score: Short Form 12
Time frame: Evaluated at 1, 12, and 24 months, measure as compared to baseline
Safety of procedure and long-term safety
Procedural and long-term safety of left bundle pacing
Time frame: 24 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Dec 2026, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
McGill University Health Centre/Research Institute of the McGill University Health Centre →